ARTICLE EphA2 Immunoconjugate as Molecularly Targeted Chemotherapy for Ovarian Carcinoma

Ovarian cancer is the most common cause of death from a gyneco-logic malignancy ( 1). Although most patients with advanced-stage ovarian cancer will die of the disease, more than 70 % have a favor-able initial response to surgery and chemotherapy and a substantial fraction will respond to second-line therapies ( 2, 3). Systemic che-motherapy is widely used but is frequently associated with intoler-able side effects ( 4). Given the high mortality rate of ovarian cancer, new therapies are urgently needed to target the tumor while sparing normal tissues